SPY434.28-8.36 -1.89%
DIA343.50-5.11 -1.47%
IXIC14,593.28-376.69 -2.52%

BRIEF-Immutep Completes Recruitment Of 2nd Line PD-1/PD-L1 Refractory NSCLC Patients In Tacti-002

reuters.com · 09/01/2021 08:36
BRIEF-Immutep Completes Recruitment Of 2nd Line PD-1/PD-L1 Refractory NSCLC Patients In Tacti-002

- Immutep Ltd IMMP:

  • IMMUTEP COMPLETES RECRUITMENT OF 2ND LINE PD-1/PD-L1 REFRACTORY NSCLC PATIENTS IN TACTI-002

  • IMMUTEP LTD - EXPECTS TO REPORT FURTHER DATA FROM TACTI-002 AT A SCIENTIFIC CONFERENCE IN CALENDAR YEAR 2021 OR EARLY CALENDAR YEAR 2022

Source text for Eikon: ID:nGNXb9wKQn

Further company coverage: IMMP


((Reuters.Briefs@thomsonreuters.com;))